EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients

Mary M Czech, Jennifer Cuellar-Rodriguez, Kyung J Kwon-Chung iD, Frida Stock, Chioma I Aneke, Kenneth N Olivier, Kevin P Fennelly, Juan Gea-Banacloche, Christa S Zerbe, Alexandra F Freeman, Steven M Holland, Michail S Lionakis iD und 1 weitere

Journal of Clinical Microbiology · 09.04.2025 · 63 (4)

DOI: 10.1128/jcm.01550-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, erschienen am 09.04.2025. Verfasst von Mary M Czech und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, M…. Hauptthemen laut MEDLINE: Antifungal Agents, Scedosporium, Mycoses, Ascomycota. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, HHS | National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reduced susceptibility to antifungals is common among members of genera Scedosporium and Lomentospora , with optimal treatments still not fully defined. In vitro antifungal susceptibility results and clinical data do not comprehensively account for the advent of new Scedosporium species identified by molecular phylogenetics. Using Clinical and Laboratory Standards Institute (CLSI) methodology, we tested a total of 103 clinical isolates obtained from patients at the NIH Clinical Center. The most frequent species were Scedosporium apiospermum (63%) and Scedosporium boydii (11%), followed by Lomentospora prolificans (7%). The novel antifungal olorofim showed the lowest MICs against all Scedosporium spp. and L. prolificans , followed by micafungin. Among the triazoles, voriconazole showed lower MICs against Scedosporium spp. Amphotericin B and posaconazole demonstrated species-specific and inter-species variable activity. Itraconazole, isavuconazole, and terbinafine had higher MIC values against Scedosporium spp. and L. prolificans . Clinical data were retrospectively reviewed for 90 isolates, of which nine patients (28 isolates) had active disease/infection and received antifungal treatment that included voriconazole or posaconazole. Five of these patients (56%) died, while three patients (33%) with chronic granulomatous disease were cured following hematopoietic cell transplantation. In 24 patients (62 isolates), the presence of the fungus was considered airway colonization. In conclusion, our data support the existence of species-specific and inter-species differences in the antifungal susceptibility patterns among members of genera Scedosporium and L. prolificans . The novel investigational antifungal olorofim may be a promising therapy. Our clinical data suggest that host status and administration of antifungal therapy most effective for each Scedosporium species complex are important determinants of outcomes. IMPORTANCE Understanding the epidemiology and clinical spectrum of infections caused by Scedosporium species complex and Lomentospora prolificans is integral to improving outcomes, particularly in severely ill and immunocompromised patients. In vitro antifungal susceptibility testing can provide an estimate of antifungal activity against fungal pathogens. Our study showed that species-specific and inter-species differences exist in the distribution of antifungal susceptibility patterns between Scedosporium and L. prolificans . Our clinical data also highlight that host status, along with effective antifungal therapy, plays a crucial role in determining treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsScedosporiumMycosesAscomycotaHumansMicrobial Sensitivity TestsMaleFemaleMiddle AgedAdultUnited StatesAgedYoung AdultAdolescentChildTriazolesDrug Resistance, FungalChild, PreschoolClinical Relevance

Stichwörter der Autor:innen

Lomentospora prolificansScedosporium speciesantifungal susceptibility testingclinical outcomes

Substanzen

Antifungal AgentsTriazoles

Autor:innen und Institutionen

  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Pulmonary Clinical Medicine Section, Cardiovascular Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Kyung J Kwon-Chung, Michail S Lionakis, Amir Seyedmousavi

Förderung

  • Intramural NIH HHS
  • HHS | National Institutes of Health (NIH)

Zitieren

APA

Czech, M. M., Cuellar-Rodriguez, J., Kwon-Chung, K. J., Stock, F., Aneke, C. I., Olivier, K. N., Fennelly, K. P., Gea-Banacloche, J., Zerbe, C. S., Freeman, A. F., Holland, S. M., Lionakis, M. S., & Seyedmousavi, A. (2025). Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients. Journal of Clinical Microbiology, 63(4). https://doi.org/10.1128/jcm.01550-24

Vancouver

Czech MM, Cuellar-Rodriguez J, Kwon-Chung KJ, Stock F, Aneke CI, Olivier KN, et al. Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients. Journal of Clinical Microbiology. 2025;63(4). doi:10.1128/jcm.01550-24

BibTeX
@article{Czech2025,
  author = {Czech, Mary M and Cuellar-Rodriguez, Jennifer and Kwon-Chung, Kyung J and Stock, Frida and Aneke, Chioma I and Olivier, Kenneth N and Fennelly, Kevin P and Gea-Banacloche, Juan and Zerbe, Christa S and Freeman, Alexandra F and Holland, Steven M and Lionakis, Michail S and Seyedmousavi, Amir},
  title = {Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  volume = {63},
  number = {4},
  doi = {10.1128/jcm.01550-24}
}
Kostenlos starten →